Myelotoxicity from chemotherapy.

Published

Journal Article (Review)

Myelosuppression continues to be a major dose-limiting toxicity for most chemotherapy regimens. While the development of growth factors has changed the approach to myelosuppression, costs remain high and can be measured both in terms of quality of life (QOL) and economic outcomes. Growing data suggest that there may also be effects on response and survival in some tumors. This review will highlight the incidence, effect, and treatment/prevention of myelosuppression and briefly discuss the questions that remain.

Full Text

Duke Authors

Cited Authors

  • Daniel, D; Crawford, J

Published Date

  • February 2006

Published In

Volume / Issue

  • 33 / 1

Start / End Page

  • 74 - 85

PubMed ID

  • 16473646

Pubmed Central ID

  • 16473646

International Standard Serial Number (ISSN)

  • 0093-7754

Digital Object Identifier (DOI)

  • 10.1053/j.seminoncol.2005.11.003

Language

  • eng

Conference Location

  • United States